News Wire

Women face several options when it comes to birth control, so potential side effects often factor into their decision. Depression is a common concern for many women, but a new study by researchers at The Ohio State University (OSU) Wexner Medical Center is putting patients at ease. It found there’s…
Allergan’s attempt to protect six Restasis patents by assigning them to the St. Regis Mohawk Tribe has hit a snag: The U.S. Patent Trial and Appeal Board (PTAB) has denied the tribe’s motion to terminate Mylan's patent challenge. "The PTAB's ruling reinforces our belief that Allergan's maneuvers…
Commercially insured patients in health plans with value-based contracts for diabetes, high cholesterol, and human immunodeficiency virus medicines in the past two years had copays that averaged 28% lower for those medicines compared to patients in other plans, according to an analysis from the Pharmaceutical…
The FDA has approved a combination of acetaminophen and the prodrug benzhydrocodone (Apadaz, KemPharm, Inc.) that the manufacturer believes is “a differentiated product for the short-term management of acute pain.”  The FDA approved the immediate-release product for the short-term (no more than…
Dulaglutide (Trulicity, Eli Lilly and Company) significantly improved HbA1C when added to ongoing type-2 diabetes treatment with a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, according to results from the phase 3b AWARD-10 trial. The data were published online in The Lancet Diabetes & Endocrinology…
Outpatient visits for flu-like illness dropped for a second week in a row but remained above the peak seen during many flu seasons, federal officials say. They predict that flu activity is likely to remain elevated for several weeks. During the week ending February 17—week 7 of this flu season—the…
The Advisory Committee on Immunization Practices (ACIP) has voted to restore the recommendation it withdrew two years ago for the use of an intranasal flu vaccine. The recommendation reflects positive results from a U.S. study in children between their second and fourth birthdays. AstraZeneca announced…
Taking a once-daily tablet of semaglutide led to “significant and superior improvements” in long-term blood sugar levels for people with diabetes in the phase 3a PIONEER1 trial, Novo Nordisk announced. PIONEER 1 is the first phase 3a trial of oral semaglutide, a new GLP-1 analogue for the treatment…
A vast research study that sought to settle a long-standing debate about whether or not antidepressant drugs really work has found they are indeed effective in relieving acute depression in adults, according to a Reuters report. The international study––a meta-analysis pooling results of 522 trials…
Elagolix (AbbVie) and low-dose hormone therapy reduced heavy menstrual bleeding among women with uterine fibroids in the phase 3 ELARIS UF-I study, with 68.5% achieving a clinical response compared with placebo (8.7%). Clinical response, measured by the alkaline hematin method, was defined as menstrual…
The FDA has approved an amantadine extended-release tablet (Osmolex ER, Osmotica Pharmaceutical) for the treatment of Parkinson’s disease and for the treatment of drug-induced extrapyramidal reactions in adults. Extrapyramidal symptoms are known side effects of many common medications. Osmolex ER…
A mass shooting at a Florida high school that left 17 people dead has reopened a debate in Congress about loosening long-standing restrictions on Centers for Disease Control and Prevention (CDC) research into gun violence, according to an article in The Hill. Democrats have frequently railed against…
Less than one week after it scored approval from the FDA for Glatopa (glatiramer acetate injection), a generic version of Teva’s multiple sclerosis drug Copaxone, Novartis may be looking to sell off its generics subsidiary Sandoz, BioSpace reports. Citing unnamed sources “familiar with the matter,”…
To keep rising health care costs in check, many health insurers have adopted a strategy known as “step therapy,” a policy requiring patients to try cheaper drugs first—and find them to be ineffective—before approving pricier medication. However, some health care experts contend the approach,…
Aimmune Therapeutics, Inc., has announced that its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares up 18% pre-market, Reuters reports. The positive trial data comes nearly four months after French drug developer DBV Technologies SA’s stick-on patch…

Pages